Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Rhea-AI Summary
Penumbra (NYSE:PEN) received U.S. FDA clearance for THUNDERBOLT, a computer assisted vacuum thrombectomy (CAVT) system for acute ischemic stroke. The platform delivers modulated aspiration to detect, fatigue and ingest clot at the occlusion, aiming for faster, more complete clot removal.
According to Penumbra, THUNDERBOLT is the first and only CAVT device cleared for stroke treatment in the U.S. and will be packaged with selected RED aspiration catheters.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- FDA clearance for THUNDERBOLT CAVT system in acute ischemic stroke
- First and only CAVT device available for stroke treatment in the U.S.
- Extends Penumbra’s CAVT technology into neurovascular stroke applications
- Bundled with existing RED aspiration catheters, supporting portfolio integration
Negative
- None.
News Market Reaction – PEN
On the day this news was published, PEN gained 0.08%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | +0.1% | Reported Q1 2026 revenue growth across thrombectomy and embolization segments. |
| Apr 13 | Clinical trial data | Positive | +0.5% | Released positive STORM-PE trial results showing improved outcomes with CAVT. |
| Feb 25 | Q4/FY 2025 earnings | Positive | -0.3% | Announced strong Q4 and full-year 2025 revenue and margin improvement. |
| Feb 04 | Acquirer earnings | Positive | -4.5% | Boston Scientific reported strong results and highlighted planned Penumbra acquisition. |
| Jan 15 | Prelim results | Positive | +11.8% | Issued preliminary Q4 and FY 2025 revenue and margin guidance above prior year. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with positive fundamentals or clinical data has usually led to modestly positive reactions, though there are notable instances where strong news was followed by a negative move.
Over the past six months, Penumbra has combined strong financial growth with major strategic developments. Earnings updates on Jan 15, Feb 25, and May 6 showed double‑digit revenue growth and solid margins. Clinical data on Apr 13 highlighted meaningful benefits from its CAVT technology in pulmonary embolism. In parallel, Boston Scientific agreed to acquire Penumbra in a transaction valuing each share at $374. Today’s FDA clearance for THUNDERBOLT extends this CAVT platform into acute ischemic stroke, building on that growth and innovation trajectory.
Regulatory & Risk Context
Key Terms
acute ischemic stroke medical
thrombectomy medical
computer assisted vacuum thrombectomy medical
aspiration thrombectomy catheters medical
occlusion medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal
"Stroke is the second leading cause of death worldwide and with stroke, timing is critical. If the blood clot isn't removed and the artery reopened quickly, patients can face severe disability or even death," said Donald Frei, M.D., neurointerventional radiologist at Swedish Medical Center,
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra's neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
"Modulated aspiration may facilitate more consistent and complete clot removal when used in conjunction with standard aspiration thrombectomy catheters," said David Fiorella, MD, PhD, director of the Cerebrovascular Center at Stony Brook University Hospital. "Our early experience with THUNDERBOLT within the context of the trial, suggests that this technology will meaningfully change how we approach stroke treatment, and could substantively improve outcomes in patients with emergent large vessel occlusion."
A recent analysis estimates that stroke mortality worldwide is projected to increase by
"Penumbra was founded to redefine stroke care and THUNDERBOLT delivers on that promise," said Shruthi Narayan, president of Penumbra. "We are uniquely positioned as the only company offering CAVT technology across both vascular and neurovascular conditions — redefining blood clot care from head-to-toe. Penumbra has delivered more than two decades of innovation, and THUNDERBOLT marks the beginning of a new era in stroke management, one that we believe will fundamentally change outcomes for patients."
THUNDERBOLT will be pre-packaged with one of Penumbra's market-leading catheters - RED™ 62, RED 68, RED 72 SILVER LABEL or RED 72 SILVER LABEL with SENDit™ technology.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety, and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Important Safety Information
Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please visit www.peninc.info/risk for the complete IFU Summary Statements.
The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management's attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025, which we filed on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Contact | ||
Jennifer Heth | Parinaz Farzin | |
Penumbra, Inc | Merryman Communications | |
510-995-9791 | 310.600.6746 |
i "Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission". The Lancet. Accessed on November 13, 2025. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00277-6/fulltext | ||||
ii "2024 Heart Disease and Stroke Statistics Update Fact Sheet". American Heart Association. Accessed on November 13, 2025. https://www.heart.org/-/media/PHD-Files-2/Science-News/2/2024-Heart-and-Stroke-Stat-Update/2024-Statistics-At-A-Glance-final_2024.pdf | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbras-thunderbolt-receives-fda-clearance---bringing-computer-assisted-vacuum-thrombectomy-technology-to-stroke-302798514.html
SOURCE Penumbra, Inc.